CN1553815A - 用于肌内给药的氟维司群药物制剂 - Google Patents

用于肌内给药的氟维司群药物制剂 Download PDF

Info

Publication number
CN1553815A
CN1553815A CNA028171888A CN02817188A CN1553815A CN 1553815 A CN1553815 A CN 1553815A CN A028171888 A CNA028171888 A CN A028171888A CN 02817188 A CN02817188 A CN 02817188A CN 1553815 A CN1553815 A CN 1553815A
Authority
CN
China
Prior art keywords
weight
volume
fulvestrant
preparation
ethanol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028171888A
Other languages
English (en)
Chinese (zh)
Inventor
J��K������ϣ
J·K·卡希尔
P·R·盖勒特
���ŷ�
A·M·欧文
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0116619.8A external-priority patent/GB0116619D0/en
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN1553815A publication Critical patent/CN1553815A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
CNA028171888A 2001-07-07 2002-07-03 用于肌内给药的氟维司群药物制剂 Pending CN1553815A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB0116619.8A GB0116619D0 (en) 2001-07-07 2001-07-07 Formulation
GB0116619.8 2001-07-07
US31571101P 2001-08-30 2001-08-30
US60/315,711 2001-08-30

Publications (1)

Publication Number Publication Date
CN1553815A true CN1553815A (zh) 2004-12-08

Family

ID=26246290

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA028171888A Pending CN1553815A (zh) 2001-07-07 2002-07-03 用于肌内给药的氟维司群药物制剂

Country Status (15)

Country Link
EP (1) EP1406662A1 (is)
JP (1) JP2004534093A (is)
CN (1) CN1553815A (is)
AR (1) AR037138A1 (is)
BR (1) BR0210898A (is)
CA (1) CA2453111A1 (is)
CO (1) CO5560585A2 (is)
HU (1) HUP0400115A3 (is)
IL (1) IL159576A0 (is)
IS (1) IS7097A (is)
MX (1) MXPA04000028A (is)
NO (1) NO20040047L (is)
PL (1) PL367624A1 (is)
RU (1) RU2004102393A (is)
WO (1) WO2003006064A1 (is)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011022861A1 (zh) 2009-08-31 2011-03-03 西安力邦医药科技有限责任公司 氟维司群纳米球/微球及其制备方法和用途
CN102600073A (zh) * 2012-03-31 2012-07-25 加拿大力邦制药有限公司 以乳酸酯为基础的氟维司群或其衍生物油性制剂及其制备方法
CN102600064A (zh) * 2012-03-31 2012-07-25 西安力邦制药有限公司 氟维司群或其衍生物缓释制剂及其制备方法
CN102600065A (zh) * 2012-03-31 2012-07-25 加拿大力邦制药有限公司 一种氟维司群或其衍生物油性制剂及其制备方法
CN111481559A (zh) * 2019-01-25 2020-08-04 江苏恒瑞医药股份有限公司 一种高浓度的氟维司群组合物及其制备方法
CN113260353A (zh) * 2019-12-11 2021-08-13 上海博志研新药物技术有限公司 氟维司群药物组合物、其制备方法及应用

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
US9271990B2 (en) 2014-02-14 2016-03-01 Fresenius Kabi Usa, Llc Fulvestrant formulations
EP3441073B1 (en) * 2016-04-06 2022-02-23 FUJIFILM Corporation Medicinal composition comprising fulvestrant
US11590077B2 (en) 2016-05-06 2023-02-28 Eagle Pharmaceuticals, Inc. Fulvestrant formulations and methods of their use
IL285928B2 (en) * 2016-05-06 2025-06-01 Eagle Pharmaceuticals Inc Fulvestrant formulations and methods of their use
JP6611932B2 (ja) 2016-05-31 2019-11-27 富士フイルム株式会社 医薬組成物
EP3706719A1 (en) 2017-11-08 2020-09-16 Eagle Pharmaceuticals, Inc. Fulvestrant formulations and methods of their use
US20210169897A1 (en) * 2017-12-07 2021-06-10 Nevakar Inc. Concentrated Fulvestrant Compositions
CN111465398A (zh) * 2018-01-31 2020-07-28 富士胶片株式会社 注射用制剂的制造方法
JP2024545690A (ja) * 2021-12-20 2024-12-10 サムヤン、ホールディングス、コーポレーション 溶解度が改善されたフルベストラントの医薬組成物及びその製造方法
CN118717660B (zh) * 2024-06-12 2025-02-28 湖州亚瑟制药有限公司 一种注射用氟维司群药物组合物及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8813353D0 (en) * 1988-06-06 1988-07-13 Ici Plc Therapeutic product
GB9525194D0 (en) * 1995-12-12 1996-02-07 Zeneca Ltd Pharmaceutical composition
GB0000313D0 (en) * 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
GB0008172D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Therapy

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011022861A1 (zh) 2009-08-31 2011-03-03 西安力邦医药科技有限责任公司 氟维司群纳米球/微球及其制备方法和用途
WO2013143299A1 (zh) * 2012-03-31 2013-10-03 利邦德制药有限公司 以乳酸酯为基础的氟维司群或其衍生物油性制剂及其制备方法
CN102600064A (zh) * 2012-03-31 2012-07-25 西安力邦制药有限公司 氟维司群或其衍生物缓释制剂及其制备方法
CN102600065A (zh) * 2012-03-31 2012-07-25 加拿大力邦制药有限公司 一种氟维司群或其衍生物油性制剂及其制备方法
WO2013143298A1 (zh) * 2012-03-31 2013-10-03 利邦德制药有限公司 一种氟维司群或其衍生物油性制剂及其制备方法
WO2013143300A1 (zh) * 2012-03-31 2013-10-03 西安力邦制药有限公司 氟维司群或其衍生物缓释制剂及其制备方法
CN102600073A (zh) * 2012-03-31 2012-07-25 加拿大力邦制药有限公司 以乳酸酯为基础的氟维司群或其衍生物油性制剂及其制备方法
CN102600073B (zh) * 2012-03-31 2014-01-01 莱普德制药有限公司 以乳酸酯为基础的氟维司群或其衍生物油性制剂及其制备方法
CN102600065B (zh) * 2012-03-31 2014-08-13 莱普德制药有限公司 一种氟维司群或其衍生物油性制剂及其制备方法
US10568890B2 (en) 2012-03-31 2020-02-25 Xi'an Libang Pharmaceutical Co., Ltd Lactate-based fulvestrant or fulvestrant derivative oily preparation and preparation method thereof
CN111481559A (zh) * 2019-01-25 2020-08-04 江苏恒瑞医药股份有限公司 一种高浓度的氟维司群组合物及其制备方法
CN111481559B (zh) * 2019-01-25 2021-10-08 江苏恒瑞医药股份有限公司 一种高浓度的氟维司群组合物及其制备方法
CN113260353A (zh) * 2019-12-11 2021-08-13 上海博志研新药物技术有限公司 氟维司群药物组合物、其制备方法及应用

Also Published As

Publication number Publication date
WO2003006064A1 (en) 2003-01-23
CA2453111A1 (en) 2003-01-23
MXPA04000028A (es) 2004-05-21
JP2004534093A (ja) 2004-11-11
CO5560585A2 (es) 2005-09-30
BR0210898A (pt) 2004-06-22
AR037138A1 (es) 2004-10-27
IL159576A0 (en) 2004-06-01
EP1406662A1 (en) 2004-04-14
NO20040047L (no) 2004-02-23
IS7097A (is) 2004-01-05
HUP0400115A2 (hu) 2004-06-28
PL367624A1 (en) 2005-03-07
HUP0400115A3 (en) 2005-11-28
RU2004102393A (ru) 2005-03-27

Similar Documents

Publication Publication Date Title
CN1553815A (zh) 用于肌内给药的氟维司群药物制剂
CN1089583C (zh) 霉酚酸2－(4－吗啉代)乙酯高剂量口服悬浮剂
CN1239158C (zh) 2－甲基－噻吩并－苯并二氮杂䓬制剂
CN1048397C (zh) 水凝胶缓释剂
CN1212154C (zh) 用于抗细胞增生剂的凝胶释药赋形剂
CN1304005C (zh) 受体酪氨酸激酶抑制剂和α1－酸性糖蛋白结合化合物的联合形式
CN1091314A (zh) 含有降钙素的药物组合物
CN1826100A (zh) 控释制剂
CN1097420A (zh) 3-芳酰基苯并[b]噻吩的磺酸酯和氨基甲酸酯衍生物
CN101050194A (zh) 双环辛烷类衍生物、其制备方法及其在医药上的用途
CN1404829A (zh) 用于抑制皮脂生成的蜡酯和胆固醇酯合成的双重抑制剂
CN101048180A (zh) 具有改善的溶解度和稳定性的固体制剂和用于制备所述制剂的方法
CN1217719A (zh) 新型苯并呋喃酮衍生物及其制备方法
CN1076972C (zh) 经皮肤给药的基剂组合物及其药剂组合物
CN1320038A (zh) 2－甲基－噻吩并－苯并二氮杂䓬制剂
CN1668583A (zh) 视黄醇衍生物、它们在治疗癌症和增强其它细胞毒性剂功效中的应用
CN1796401A (zh) 五环三萜类衍生物及其制备方法和用途
CN1220490C (zh) 哌嗪环氧乙烷衍生物在制备用于诱导肿瘤细胞死亡的药物中的应用
CN1272059A (zh) 类胡萝卜素制剂
CN1022103C (zh) 制备取代苯乙烯衍生物及其药用酸加成盐和其季铵盐的方法
CN1307989C (zh) 植烷酸在制备治疗糖尿病的药物中的用途
CN1814601A (zh) 具有免疫抑制作用的青蒿素衍生物及药物组合物
CN1939461A (zh) 一种中药复方制剂的质量控制方法
CN1915217A (zh) 复方蒿甲醚自乳化剂
CN1557352A (zh) 菊苣水提取物的新用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication